Chemists Fight Cancer with Open Science
In the fight against diffuse intrinsic pontine glioma (DIPG) pediatric brain cancer, chemists at Charles River are using an open science approach to get the best science in the fastest way possible. Under the leadership of Meds4Kids Pharma (M4K), Charles River and other open science partners have identified potent, selective, brain penetrant ALK2 inhibitors which will be critical in developing therapies that will extend the life of DIPG patients.
Sharing knowledge, regulatory data protections, and market incentives, an “open science” framework can accelerate drug development. Our upcoming webinar, “Tackling DIPG with Open Science, highlights scientific advancements and recent data but will also include insights into the open science framework.